MannKind Co. (NASDAQ:MNKD) has earned an average recommendation of “Buy” from the six analysts that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $3.00.
A number of research analysts have recently issued reports on MNKD shares. BidaskClub raised MannKind from a “sell” rating to a “hold” rating in a report on Thursday. ValuEngine raised MannKind from a “sell” rating to a “hold” rating in a report on Thursday, August 1st.
Large investors have recently made changes to their positions in the company. Greatmark Investment Partners Inc. bought a new position in shares of MannKind during the first quarter valued at $25,000. Integrated Wealth Concepts LLC bought a new position in shares of MannKind during the second quarter valued at $68,000. Cubist Systematic Strategies LLC bought a new position in shares of MannKind during the second quarter valued at $33,000. Janus Henderson Group PLC lifted its holdings in MannKind by 91.5% in the first quarter. Janus Henderson Group PLC now owns 32,976 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 15,757 shares during the period. Finally, LPL Financial LLC lifted its holdings in MannKind by 86.8% in the second quarter. LPL Financial LLC now owns 33,927 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 15,765 shares during the period. 26.64% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ:MNKD opened at $1.43 on Tuesday. The company has a market cap of $271.15 million, a P/E ratio of -2.42 and a beta of 2.37. MannKind has a 1 year low of $0.94 and a 1 year high of $2.34. The stock’s fifty day moving average price is $1.12 and its 200-day moving average price is $1.38.
MannKind (NASDAQ:MNKD) last announced its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). The business had revenue of $15.00 million for the quarter, compared to the consensus estimate of $14.83 million. During the same period in the previous year, the company earned ($0.16) earnings per share. On average, sell-side analysts expect that MannKind will post -0.3 EPS for the current year.
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States.
Recommended Story: How is a buy-side analyst different from a sell-side analyst?
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.